Record quarterly net revenues for Q4 2025 were $247.1 million, an increase of 29.6% year-over-year. Record full year net revenues for 2025 were $883.4 million, an increase of 43.8% year-over-year. Total Rare Disease net revenue for Q4 2025 was $131.3 million, up 50.8% year-over-year, and $422.6 million for full year 2025, up 84.1% year-over-year. Cortrophin Gel net revenues were $111.4 million for Q4 2025, an 87.6% increase year-over-year, and $347.8 million for full year 2025, a 75.6% increase year-over-year. ILUVIEN and YUTIQ net revenues were $19.8 million for Q4 2025 and $74.9 million for full year 2025. GAAP net income available to common shareholders was $27.5 million for Q4 2025 and $77.2 million for full year 2025. Record adjusted non-GAAP EBITDA was $65.4 million for Q4 2025, up 30.6% year-over-year, and $229.8 million for full year 2025, up 47.3% year-over-year. Diluted GAAP income per share was $1.18 for Q4 2025 and $3.32 for full year 2025. Adjusted non-GAAP diluted earnings per share was $2.33 for Q4 2025 and $7.89 for full year 2025. Generics net revenues were $100.8 million in Q4 2025, an increase of 28.2% year-over-year, and $384.1 million for full year 2025, an increase of 27.6% year-over-year. Brands net revenues were $12.3 million for Q4 2025, a decrease of 37.9% year-over-year, and $61.3 million for full year 2025, a decrease of 5.3% year-over-year. As of December 31, 2025, the company had $285.6 million in unrestricted cash and cash equivalents and generated $185.2 million in cash flow from operations in 2025. The company reaffirmed its full year 2026 financial guidance, expecting total net revenues between $1,055 million and $1,115 million, and adjusted non-GAAP EBITDA between $275 million and $290 million.